Drug intelligence / Profile preview

CBSD-EXO

Development stage: Preclinical
Lead developer: Exomas
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Cell Therapies

Overview

CBSD-EXO is a neural stem cell (NSC)-derived exosome therapy under development by Exomas for the treatment of neurodegenerative diseases. As an extracellular vesicle-based biologic, CBSD-EXO is designed to promote neuroregeneration by inducing NSC proliferation and stimulating neuronal differentiation, including increased neurite outgrowth and dendritic spine density. The therapy also exhibits neuroprotective properties by preventing neuronal apoptosis and restoring neuronal morphology and function. While academic research associated with the program highlights its potential in Parkinson's disease, the candidate is currently positioned for broad applications in neurodegeneration.

Other names: neural stem cell-derived exosomesNSC-derived exosomes

Beyond the preview

Go deeper on CBSD-EXO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBSD-EXO.

Explore the full profile